Taylor A, Surgenor T, Thomson D K, Graham R J, Oettgen H
Exp Eye Res. 1984 Mar;38(3):217-29. doi: 10.1016/0014-4835(84)90160-x.
Antisera specific for leucine aminopeptidase (LAP) were prepared. Using these antisera in immunodiffusion tests, the identity of LAP isolated from beef lens and kidney is demonstrated. The same pertains to hog lens and kidney LAP. As indicated by only partial fusion of the immunoprecipitates in immunodiffusion plates, leucine aminopeptidases isolated from hog and beef are antigenically similar but not identical. These tests also indicate substantial similarity between a component in human lens homogenates and bovine or hog LAP. Microcomplement fixation tests corroborate these observations and indicate that, under these conditions, LAP from beef lens and kidney, or hog lens and kidney, are indistinguishable. However, there is an approximate 8.5% amino acid sequence difference between beef and hog LAP. Microcomplement fixation tests with human lens homogenate also corroborate immunodiffusion results and indicate an approximate 19% amino acid sequence difference between beef and human LAP. These data establish that LAP is a species-specific enzyme and they indicate that it is not organ specific. Maximal complement fixation occurs at approximately 0.1 microgram antigen per tube in those assays in which pure aminopeptidases were tested. This permits standardization of the microcomplement fixation assay for LAP under these conditions. Maximal complement fixation occurs at 160-200 micrograms human lens homogenate per tube. Assuming that in this quantity of homogenate there is 0.1 microgram LAP, then it can be calculated that LAP comprises about 0.05% of the lens protein. This agrees closely with the percentage of LAP in hog and beef lenses. Thus, the reduced LAP activity reported for human lens tissue appears not to result from an absence of the enzyme but rather, may be due to diminished catalytic competency of the enzyme in aged human lens tissue (see Taylor and Juhngen , 1984). The unit evolutionary period, 4.7-5.8 X 10(6) years, indicates that LAP has been highly conserved during evolution.
制备了对亮氨酸氨肽酶(LAP)具有特异性的抗血清。在免疫扩散试验中使用这些抗血清,证明了从牛肉晶状体和肾脏中分离出的LAP具有同一性。猪晶状体和肾脏LAP也是如此。如免疫扩散板中免疫沉淀物仅部分融合所示,从猪和牛肉中分离出的亮氨酸氨肽酶在抗原性上相似但不相同。这些试验还表明,人晶状体匀浆中的一种成分与牛或猪LAP之间存在显著相似性。微量补体结合试验证实了这些观察结果,并表明在这些条件下,来自牛肉晶状体和肾脏或猪晶状体和肾脏的LAP无法区分。然而,牛肉和猪LAP之间存在约8.5%的氨基酸序列差异。用人晶状体匀浆进行的微量补体结合试验也证实了免疫扩散结果,并表明牛肉和人LAP之间存在约19%的氨基酸序列差异。这些数据表明LAP是一种物种特异性酶,并且表明它不是器官特异性的。在测试纯氨肽酶的那些试验中,每管最大补体结合发生在约0.1微克抗原时。这使得在这些条件下LAP的微量补体结合试验能够标准化。每管最大补体结合发生在160 - 200微克人晶状体匀浆时。假设在这个量的匀浆中有0.1微克LAP,那么可以计算出LAP约占晶状体蛋白的0.05%。这与猪和牛肉晶状体中LAP的百分比非常接近。因此,报道的人晶状体组织中LAP活性降低似乎不是由于该酶的缺失,而是可能由于老年人类晶状体组织中该酶的催化能力下降(见Taylor和Juhngen,1984)。单位进化期为4.7 - 5.8×10⁶年,表明LAP在进化过程中一直高度保守。